RxDoctor Payments Data

Raymond Mak, MD

Radiation Oncology · Boston, MANPI 1285784041

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (58.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by AstraZeneca at 41.1% of the total. Reporting peaked in 2024 at $10,724 and has fallen 76.7% since, to $2,500 in 2025. Among radiation oncology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,167in general payments, 2019–2025

Across 25 payments — averaging $1446.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$15K
  • Viewray Technologies Inc$14K
  • Novartis$3K
  • Pfizer$3K
  • Siemens Medical Solutions USA, Inc.$1K
$172,251in research payments, 2019–2025

Across 11 payments — averaging $15,659 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viewray Technologies Inc$94K
  • AstraZeneca$78K

What the payments were for

  • Consulting fees$21,18259%
  • Speaking & faculty fees$12,50035%
  • Travel & lodging$2,0736%
  • Food & beverage$4131%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca5$14,877
Viewray Technologies Inc16$14,478
Novartis1$3,300
Pfizer1$2,500
Siemens Medical Solutions USA, Inc.2$1,013

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,167 in reported general payments places this provider in the 95th percentile of 200 radiation oncology providers in Massachusetts.

See all radiation oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$175,897
Medicare patients
229
Services billed
1,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →